If you double dose patients and compare them to external comparators that didn't, when you cherry-pick a patient population of the most healthy GBM patients and compare the results to external trials that allow less health patients you have a biased trial.
Any trial that repeatedly doses patients is going to get better results.
NWBO has the data of those that were diagnosed as pseudoprogression and those with clinical progress -- they seem reticent to release it even though it was a secondary endpoint of their new protocol. Best was to demonstrate the difference in the final results. Why wouldn't you include it in you JAM Oncology manuscript??
Market Data 
Markets 
AI
